VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.50 price target on shares of VolitionRx in a research note on Thursday, May 16th.

VolitionRx Stock Down 6.4 %

Shares of VNRX opened at $0.69 on Thursday. The stock has a market capitalization of $57.36 million, a P/E ratio of -1.51 and a beta of 1.16. VolitionRx has a twelve month low of $0.55 and a twelve month high of $1.79. The firm has a fifty day simple moving average of $0.75 and a two-hundred day simple moving average of $0.84.

VolitionRx (NYSE:VNRX) last posted its earnings results on Monday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. Sell-side analysts expect that VolitionRx will post -0.34 EPS for the current fiscal year.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of VolitionRx Limited (NYSE:VNRX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned approximately 0.19% of VolitionRx as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.